Brendon Neuen

The George Institute for Global Health

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (13)

Hiddo Lambers Heerspink

University of Groningen

NETHERLANDS

View details

Michael Tsoukas

Assistant Professor of Medicine

McGill University Health Centre

CANADA

View details

Clare Arnott

AUSTRALIA

View details

Rajiv Agarwal

Professor of Medicine

Indiana State University

UNITED STATES

View details

Jasper Stevens

NETHERLANDS

View details

Pardeep Jhund

University of Glasgow

UNITED KINGDOM

View details

Jochen Seufert

GERMANY

View details

Gian Luca Di Tanna

Visiting Professor

University of New South Wales

AUSTRALIA

View details

george bakris

Professor of medicine, Director AHA Comprehensive Hypertension Center

University of Chicago

UNITED STATES

View details

Kieran Docherty

University of Glasgow

UNITED KINGDOM

View details

Megumi Oshima

Kanazawa University

JAPAN

View details

Adeera Levin

CANADA

View details

Lauren Houston

Conjoint Lecturer

University of New South Wales - Randwick Campus

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Brendon Neuen

Research Interests

Explore related searches

Contact this professor

Articles (10)

The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials

The effects of canagliflozin in type 2 diabetes in subgroups defined by population‐specific body mass index: Insights from the CANVAS Program and CREDENCE trial

Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.

Empagliflozin in Patients with Chronic Kidney Disease.

Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR

Collaborators (13)

Hiddo Lambers Heerspink

Michael Tsoukas

Clare Arnott

Rajiv Agarwal

Jasper Stevens

Pardeep Jhund

Jochen Seufert

Gian Luca Di Tanna

george bakris

Kieran Docherty

Megumi Oshima

Adeera Levin

Lauren Houston

Make your next move.